Abnormal activation of GSK-3β signaling pathways is implicated in the etiology of psychiatric disease; inhibition of the kinase has been proposed to be of therapeutic benefit in psychosis and bipolar diseases (Nakazawa et al. 2001; Beaulieu et al. 2009; Alimohamad et al. 2005; Li et al. 2007). This evidence concerns the gene GSK3B and psychiatric disorder.